Acrylamide (AM), used in the manufacture of polyacrylamide and grouting agents, is produced during the cooking of foods. Workplace exposure to AM can occur through the dermal and inhalation routes. The objective of this study was to define the kinetics of elimination of AM and its metabolites following oral and dermal administration. This is the second part of a study in which metabolites and hemoglobin adducts of AM were determined in people (Fennell et al., 2005, Toxicol. Sci. 85, 447-459). (1,2,3-13 C 3 )AM was administered in an aqueous solution orally (single dose of 0.5, 1.0, or 3.0 mg/kg) or dermally (three daily doses of 3.0 mg/kg) to sterile male volunteers. Urine samples were collected at 0-2, 2-4, 4-8, 8-16, and 16-24 h following administration orally, or at 0-2, 2-4, 4-8, 8-16, and 16-24 h following each of three daily dermal doses.
Acrylamide (AM), used in the manufacture of polyacrylamide and grouting agents, is produced during the cooking of foods. Workplace exposure to AM can occur through the dermal and inhalation routes. The objective of this study was to define the kinetics of elimination of AM and its metabolites following oral and dermal administration. This is the second part of a study in which metabolites and hemoglobin adducts of AM were determined in people (Fennell et al., 2005, Toxicol. Sci. 85, 447-459) . (1,2,3-13 C 3 )AM was administered in an aqueous solution orally (single dose of 0.5, 1.0, or 3.0 mg/kg) or dermally (three daily doses of 3.0 mg/kg) to sterile male volunteers. Urine samples were collected at 0-2, 2-4, [4] [5] [6] [7] [8] [8] [9] [10] [11] [12] [13] [14] [15] [16] , and 16-24 h following administration orally, or at 0-2, 2-4, [4] [5] [6] [7] [8] [8] [9] [10] [11] [12] [13] [14] [15] [16] , and 16-24 h following each of three daily dermal doses.
13 C 3 -AM and its metabolites in urine, 13 C 3 -glycidamide, 13 C 3 -N-acetyl-S-(3-amino-3-oxopropyl)cysteine and its S-oxide, and 13 C 3 -N-acetyl-S-(3-amino-2-hydroxy-3-oxopropyl)cysteine, were quantitated using liquid chromatography-tandem mass spectrometry. The recovered urinary metabolites accounted for 45.6, 49.9, and 39.9% of a 0.5, 1.0, and 3.0 mg/kg oral dose (0-24 h), respectively, and for 4.5% of the dose after 3 mg/kg was administered daily for 3 days dermally (0-4 days). These results indicate that after oral administration AM is rapidly absorbed and eliminated. The half-life estimated for elimination of AM in urine was 3.1-3.5 h. After dermal administration, AM uptake is slow. This study indicated that skin provides a barrier that slows the absorption of AM, and results in limited systemic availability following dermal exposure to AM.
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Acrylamide (AM) is used in the manufacture of polyacrylamide, and is used in grouting agents. Polyacrylamide is used in the manufacture of paper, for sludge dewatering, as a flocculant in water treatment, and is used in the manufacture of consumer products. Concern over human exposure has been primarily with workplace exposure to grouting agents, with dermal and inhalation exposure the most likely routes (European Union, 2002) .
The discovery of AM in fried and baked foods (Rosen and Hellenas, 2002; Tareke et al., 2000 Tareke et al., , 2002 has aroused considerable concern about the potential health effects of the widespread exposure to low levels of AM in foods (WHO, 2002) .
AM is carcinogenic in rats (Friedman et al., 1995; Johnson et al., 1986) , producing mammary gland adenocarcinomas and fibroadenomas in female rats, thyroid follicular cell adenomas and adenocarcinomas in male and female rats, and mesotheliomas of the testicular tunic in male rats (Friedman et al., 1995) . AM is neurotoxic, inducing a characteristic peripheral neurotoxicity in animals and man Schaumburg, 1974a,b, 1975) . This toxicity is manifested as a distal to proximal loss of nerve function and dying back of cells. AM is a germ cell mutagen (Dearfield et al., 1995) , and affects rodent reproduction, producing reduced litter size. At elevated AM doses other reproductive effects are seen, likely as a consequence of dominant lethal mutations at low doses and neurotoxicity at higher doses (Tyl and Friedman, 2003) .
The role of metabolism in the mode of action of AM has been the subject of some research. AM is reactive, and can react directly with proteins. AM reacts rapidly with the sulfhydryl group of glutathione (GSH), and the N-acetylcysteine conjugate of AM is a major metabolite of AM in urine (Fig. 1) . AM also undergoes oxidation to glycidamide (GA), a reactive epoxide (Calleman et al., 1990; Sumner et al., 1992) . This metabolite is then further metabolized via hydrolysis or GSH conjugation or can react with proteins, including hemoglobin, and with DNA (Gamboa da Costa et al., 2003; Segerbäck et al., 1995) . The oxidation of AM to GA is catalyzed primarily by cytochrome P450-2E1 (Sumner et al., 1999) . One of the primary issues in risk assessment for AM is whether AM or GA is the active form in generating the various toxic effects, or whether both are capable of generating toxic effects. GA is genotoxic, reacts with DNA, and is generally assumed to be the agent of concern in carcinogenesis (Paulsson et al., 2001) . GA is thought to mediate the heritable mutational events caused by AM exposure (Favor and Shelby, 2005; Ghanayem et al., 2005a,b) . The role of AM and GA in the generation of neurotoxic effects is less clear, with one study indicating that GA is active (Abou-Donia et al., 1993) , whereas others concluded that AM is the active agent (Barber et al., 2001; Costa et al., 1992 Costa et al., , 1995 . The extent of metabolism of AM to GA is thus one of the factors to be considered in conducting a human health risk assessment.
Dermal exposure to AM has been evaluated in a number of studies, examining the penetration of AM in vitro in pig skin (Diembeck et al., 1998) , and in vivo in rodents to evaluate uptake and metabolism (Carlson and Weaver, 1985; Ramsey et al., 1984; Sumner et al., 2003) , or effects (Adler et al., 2004; Bull et al., 1984a,b; Gutierrez-Espeleta et al., 1992) . In vivo studies in rats have suggested that AM absorption when administered dermally is considerably less than the applied dose, with estimates of 1.5 and 8% of the applied dose excreted in urine from two studies. From hemoglobin adduct measurements in the same studies, 3.6 and 16.5% uptake was estimated (Sumner et al., 2003) .
The primary objectives of this study were to evaluate the conversion of AM to GA in people exposed to AM, and to evaluate the extent of uptake following dermal administration. This was conducted by administering 13 C-substituted AM to volunteers orally or dermally, and measuring urinary metabolites or hemoglobin adducts derived from the GA pathway and comparing them with those derived from AM directly. We have previously reported the initial results of this study (Fennell et al., 2005) , in which metabolites were analyzed in a single pooled sample of urine for each individual administered AM at the highest dose, using 13 C nuclear magnetic resonance (NMR) spectroscopy. This approach enabled quantitation of the total urinary metabolites excreted in the collection period, but the limited sensitivity of the method precluded analysis of lower doses administered orally, and dermal administration. Here we report further analysis, in which we have developed a sensitive liquid chromatography-tandem mass spectrometric (LC-MS/ MS) method for analysis of AM and its urinary metabolites, and applied it to urine samples collected at 0-2, 2-4, [4] [5] [6] [7] [8] [8] [9] [10] [11] [12] [13] [14] [15] [16] , and 16-24 h after administration of a single oral dose of AM (0.5, 1.0, or 3.0 mg/kg) and after one, two, and three doses of AM administered dermally (3.0 mg/kg). The objective of this study was to define the kinetics of elimination of AM and its metabolites following oral and dermal administration.
MATERIALS AND METHODS
Details of the administration of AM to human volunteers have been reported previously and are reviewed in brief below (Fennell et al., 2005) .
Institutional Review Board Approval
This study was conducted in accordance with the Code of Federal Regulations (CFR) governing Protection of Human Subjects (21 CFR 50), Institutional Review Board (IRB) (21 CFR 56), retention of data (21 CFR 312) as applicable and consistent with the Declaration of Helsinki. The administration of 13 C AM to the study subjects was conducted at Covance Clinical Laboratories. IRB approval of the protocol and the consent form was obtained at Covance Clinical Research Unit (CRU). Written informed consent was obtained from all study participants prior to study participation. IRB approval was also obtained at RTI International, where the analysis of the samples was conducted. The study participants were compensated for time spent in the Covance CRU. The stipends were reviewed by the IRB as part of the study protocol, and those approved for this study were within the general stipend range approved by the IRB for other studies conducted at Covance CRU.
Chemicals
(1,2,3-13 C 3 ) AM (CLM-813, lot number 11085, 99% labeled) was obtained from Cambridge Isotopes Limited. Identity and purity were confirmed by 1 H and 13 C NMR spectroscopy. (Note that the molecular weight of the (1,2,3-13 C 3 ) AM is 74, vs. 71.08 for natural-abundance AM.)
AM Exposure
Twenty-four volunteers participated in this study. They were all male Caucasians (with the exception of one Native American) weighing between 71 and 101 kg and between 26 and 68 years of age. All volunteers were aspermic and had not used tobacco products for the past 6 months. They passed a drug screen and had not taken prescription drugs or caffeinated products over the previous 3 days. They had not consumed alcohol-containing beverages or medications within 7 days of study entry, and for the duration of the study. Each experimental group consisted of six individuals of which one was a placebo. There were two phases to this study: an oral phase and a dermal phase.
In the oral phase, three groups of six people were administered 0.5, 1.0, or 3.0 mg/kg 13 C 3 AM. Individuals were presented with test substance at approximately 9:00 A.M. to initiate the study. Urine was collected at 0-2, 2-4, 4-8, 8-16, and 16-24 h. In the dermal phase, a 50% (wt/vol) solution of 13 C 3 AM was applied directly on the skin to a clean, dry, marked off, 24 cm 2 (3 cm 3 8 cm) area on the volar forearm. After applying the appropriate amount of material, the liquid was evaporated to dryness using a commercial hair dryer and covered with a sterile gauze pad. After drying the AM solution, the tape which had been used to demark the area of application was removed and placed in a vial containing 20 ml of water. The water (dermal dam solution) was analyzed for AM by high-performance liquid chromatography (HPLC). The site of application was covered with gauze for 24 h at which time the gauze was removed and the area was washed with 1000 ml of water. The recovered wash water was analyzed by HPLC for AM. Dermal applications alternated between left and right arms, starting with the subject's dominant arm. Blood was collected immediately prior to compound administration and 24, 48, 72, and 96 h later 
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(immediately prior to administration of the second and third doses, after gauze removal and prior to leaving the clinic). Hormone blood samples were drawn immediately prior to compound administration, after 24 h and on day 5 when the volunteers left the clinic.
Each exposure group contained six volunteers. Of the six volunteers in each group, five received the designated amount of AM, and one received no AM. AM was applied to the skin for 24 h on one forearm, and a blood sample was collected at 24 h following the first administration. This was repeated on the following 2 days, with AM applied on alternating arms, for a total of three dermal doses of AM at 24 h intervals. A total of five blood samples was collected from each volunteer administered AM dermally, on day 1 (prior to the first dose), day 2, day 3, day 4, and day 5. The sample obtained on day 5 was at 24 h following removal of the occlusion at the site of application.
Urine samples were collected at intervals of 0-2, 2-4, 4-8, 8-16, and 16-24 h following administration of AM. The volume of urine in each sample was recorded, and sample aliquots were transferred to sample vials for storage.
Urinary Metabolites of AM
Standards. Unlabeled standards were prepared for GA, cysteine-S-propionamide (CP), N-acetyl cysteine-S-propionamide (NACP), N-acetyl-S-(1-carbamoyl-2-hydroxyethyl)cysteine (GAMA2), N-acetyl-S-(3-amino-2-hydroxy-3-oxopropyl)cysteine (GAMA3), and NACP sulfoxide (Fig. 1 ).
13
C 3 -substituted standards were prepared for CP, NACP, and NACP sulfoxide.
NMR and mass spectral analysis of standards. NMR spectra were recorded using a Bruker AMX 300-MHz spectrometer, or a Varian Inova 500-MHz spectrometer. Mass spectra of standards were obtained on an Applied Biosystems (Foster City, CA) API 3000 mass spectrometer equipped with an Agilent 1100 LC and a Turboionspray interface.
Synthesis of GA. GA was synthesized by H 2 O 2 oxidation of acrylonitrile (Payne and Williams, 1961), as described previously (Fennell et al., 2003) .
Synthesis of CP. CP was synthesized by reaction of cysteine with AM in a solution of triethylamine in water, essentially as described by Calleman et al. (1990) . The identity of the product was confirmed by 1 H NMR (not shown) and by mass spectrometry.
C 3 -substituted CP was synthesized the same way except with 13 C 3 -AM. Mass spectrum, Turboionspray, direct infusion, positive ion, m/z 193. 1, 176.1, 146.9, 130.0, 103.9, 76.0, 71.9, 55.1. Mass spectrum 13 C 3 substituted, m/z 195.9, 179.1, 150.1, 133.1, 106.9, 75.2, 72.0, 58.2. Synthesis of NACP. NACP was synthesized by reacting approximately 2 mmol each of N-acetylcysteine, AM, and triethylamine in 3.6 ml of water. The reaction was incubated for 6 days at 35°C. The product was lyophilized, and purified by reverse-phase HPLC using a Waters Atlantis dC18 column (250 mm 3 4.6 mm, 5 lm). NACP was eluted with 0.1% formic acid using the same HPLC system. Substituted NACP was synthesized the same way with 13 C 3 -AM.
1 H NMR (300 MHz) d 2.08 (3H, s, CH 3 ), 2.58 (2H, t, CH 2 -CONH 2 ), 2.86 (2H, t, S-CH 2 -CH 2 ), 2.98 (1H, dd, cys b), 3.15 (1H, dd, cys b#), and 4.50 ppm (1H, dd, cys a).
Mass spectrum, Turboionspray, direct infusion, positive ion, m/z 234. 9, 216.9, 192.9, 189.3, 147.2, 130 .2, 104.1.
Mass spectrum 13 C 3 substituted, m/z 237. 9, 220.3, 195.9, 191.9, 150.2, 133 .1, 107.1.
Synthesis of GAMA. GA (1.2 mmol) was reacted with N-acetylcyteine (1.3 mmol), triethylamine (1.4 mmol), and 2 ml of water. The reaction was incubated at 35°C for 5 days. The product was purified by reverse-phase HPLC using a Waters Atlantis dC18 column (250 mm 3 4.6mm, 5 lm) with guard column, and was eluted with 0.1% formic acid using the same HPLC system. Two peaks were collected, peak A and peak B.
Peak A: 1 H NMR spectrum (300 MHz) d 2.04 (3H, s, CH 3 ), 3.0 (1H, 2 dd, cyst b), 3.15 (1H, 2 dd, cys b#), 3.55 (1H, t, S-CH-CONH 2 ), 3.80 (2H, m, S-CH-CH 2 -OH), and 4.50 ppm (1H, dd, cys a). The 1 H and the 13 C NMR spectra were consistent with the formation of a pair of diastereomers, based on the multiplicity of the signals for the cysteine b-protons, the carbon signals for the cysteine b carbon, and the methylene and methine carbons derived from AM. Based on the NMR data, this metabolite is assigned the structure GAMA2 (corresponding to metabolite 3 described in Sumner et al., 1992) .
Peak The 1 H and the 13 C NMR spectra were consistent with the formation of a pair of diastereomers based on the multiplicity of the signals for the cysteine b-protons, the carbon signals for the cysteine b carbon, and the methylene and methine carbons derived from AM. Based on the NMR data, this metabolite is assigned the structure GAMA3 (corresponding to metabolite 2 described in Sumner et al., 1992) .
Peak B: Mass spectrum, Turboionspray, direct infusion, positive ion, m/z 251.5 (MþH þ ) daughter ions at 232. 9, 209.1, 205.1, 192.1, 174.4, 163.1, 145.9, 130 .1, 120.1.
Synthesis of NACP sulfoxide. NACP (17.2 mg), water (344 ll), and H 2 O 2 (3.4 ll) were mixed and placed at 4°C overnight. The reaction was purified by reverse-phase HPLC using the same column and HPLC system as NACP. The substituted compound was synthesized similarly.
1 H NMR (500 MHz): d 1.90, 1.96 (3H, s, CH 3 ), 2.63 (2H, q, CH 2 -CONH 2 ), 2.98 (1H, m, S-CH 2a -CH 2 ), 3.11 (2H, m, S-CH 2b -CH 2 , and cys b), 3.25 and 3.50 (0.5 H each, dd, cys b#), and 4.55 ppm (1 H, 2 dd, cys a). 194.1, 180.1, 176.1, 162.1, 129.9, 125.1, 120 .1, 101.1.
Sample Preparation
Urine samples were thawed and 65 ll was taken for analysis. Internal standard solutions were prepared with individual standard at concentrations of 20 lg/ml, except for GA and NACP which were used at a concentration of 80 lg/ml. Each unlabeled internal standard solution (5 ll of each) was added to each sample and standard curve sample to give a final volume of 100 ll. Each sample was vortexed and centrifuged at 14,000 rpm for 2 min, and 10 ll was transferred to a microfuge tube. Ninety microliters of water was added and the tubes were vortexed and centrifuged at 14,000 rpm for 2 min. The sample was transferred to a low volume insert for LC-MS/MS analysis.
LC-MS/MS Analysis of Urinary Metabolites
An API 3000 LC-MS/MS system with Agilent 1100 binary pump, degasser, and autosampler was used for analysis. The column used was a Waters (Milford, MA) Atlantis dC18 (250 mm 3 4.6 mm, 5 lm), with guard column. The flow rate was 1 ml/min and was split with 50% going to the MS/MS. AM and its metabolites were eluted with 0.1% formic acid in water. After 25 min, the column was washed with 95% acetonitrile, and 5% of 0.1% formic acid in water for 5 min. A 5-min gradient was run to return the column to its starting conditions, and reequilibration was conducted for 10 min.
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The sample injection volume was 10 ll. Elution was monitored by multiple reaction monitoring (MRM) in the positive ion mode. The ion source was Turboionspray. The nebulizer gas was set at 10 (arbitrary units), the curtain gas at 8, the collision gas was set at 4, the ionization voltage was set at 4500 V, and the source temperature was 500°C.
Analysis was conducted by selected reaction monitoring (SRM) of selected precursor / product ion transitions for each analyte and unlabeled standard: Standard curves were used to calculate the concentration of each metabolite in urine when available (AM, CP, NACP, and NACP sulfoxide). Other metabolites were quantitated by the ratio of analyte to the internal standard added. The range of concentrations used for standard curves provided a linear response, and is indicated below: AM, range 0.1-10 lg/ml, r 2 ¼ 0.998 CP, range 0.1-5 lg/ml, r 2 ¼ 0.995 NACP, range 0.5-200 lg/ml, r 2 ¼ 0.983 NACP sulfoxide, range 0.1-100 lg/ml, r 2 ¼ 0.993.
For each metabolite, a limit of quantitation (LOQ, signal:noise of 10:1) and a limit of detection (LOD, signal:noise of 3:1) corresponded to
Analyses were conduced in duplicate, with triplicate standard curves, and with quality control standards incorporated.
Pharmacokinetic Analysis of Urinary AM
The kinetics of AM elimination in urine following oral administration of AM were analyzed using WinNonlin version 4.0.1 from Pharsight (Cary, NC). Noncompartmental analysis using Model 210 for extravascular input and urine data was used to calculate the elimination rate constant and half-life.
RESULTS
With one exception, the major metabolites of AM have been previously reported, and characterized (Calleman et al., 1990; Dixit et al., 1982; Sumner et al., 1992) . We have recently reported the detection of a sulfoxide metabolite of NACP in human urine by 13 C NMR spectroscopy (Fennell et al., 2005) . Here we have verified that the chemical shifts reported in urine for the metabolite detected by 13 C NMR (6b, 27.60 ppm; 6a, 46.47 ppm; and 6c, 175.4 ppm) correspond to the signals assigned to the AM-derived carbon atoms in a synthetic standard (27.88 and 27.95 for S-CH 2 -CH 2 ; 46.89 and 46.94 for CH 2 -CONH 2 ; 175.75 and 175.78 for CONH 2 ). The standard consisted of a pair of diastereomers, which could be separated by HPLC.
Method Development for Analysis of Urinary Metabolites
A sensitive method for quantitation of urinary metabolites of AM was developed using LC-MS/MS. The metabolites investigated were chosen based on our previous study, which involved the identification and quantitation of urinary metabolites of (1,2,3-13 C 3 ) AM by NMR spectroscopy (Fennell et al., 2005) . Unlabeled standards were prepared for GA, glyceramide, NACP, CP, NACP sulfoxide, GAMA3, and GAMA2. Isotope-substituted standards were prepared for NACP, CP, and NACP sulfoxide, using (1,2,3-13 C 3 ) AM as starting material. Standard curves were prepared for the isotope-substituted standards, and natural-abundance standards. However, since the administered material was (1,2,3-13 C 3 ) AM, the analyte standard was the isotope-substituted form, and the internal standard was the natural-abundance form. Concentrations were calculated using the ratio of analyte:internal standard from the standard curve. For metabolites for which there was no isotopesubstituted standard available (derived from GA), the ratio of analyte:internal standard was used directly to calculate the concentration of analyte. Urine samples were prepared directly by addition of internal standards, dilution, and centrifugation.
For chromatographic separation of AM and its metabolites, isocratic elution with 0.1% formic acid in water was used. This enabled the early elution of ion-suppressing materials from the column, and permitted the retention of AM and GA and the resolution of the diastereomers of NACP sulfoxide, GAMA2, and GAMA3. A representative chromatogram of a urine sample from a subject administered 13 C 3 AM orally in Figure 2 shows the peaks derived from the isotope-substituted metabolites of 13 C 3 -AM. LC-MS/MS in the positive ion mode enabled the sensitive detection of each of the metabolites of interest. The chromatograms associated with the naturalabundance standards are available in Supplementary Data. AM and GA could be readily identified and quantitated: 1,2,3-13 C 3 AM appears as a single peak in Figure 2A , with a retention time of 7.1 min, and 1,2,3-13 C 3 GA (Fig. 2B ) had a retention time of 5.4 min. However, glyceramide was poorly retained on a variety of columns evaluated, and could not be quantitated because of the interference from ion-suppressing materials in urine that coeluted with glyceramide. Thus, the data in this paper are presented without the quantitation of glyceramide.
Resolution of the metabolites derived from GSH conjugation also required isocratic elution with 0.1% formic acid in water. 13 C 3 -CP (MRM 196 / 107) was eluted at a retention time of 4.1 min (Fig. 2C ). Peaks were observed at other retention times for the precursor / product ion transition of m/z 196 / 107, but were clearly resolved from 13 C 3 -CP. The major metabolite which gave this transition, as well as m/z 238 / 196 was 13 C 3 -NACP at a retention time of 23.9 min (Fig. 2D) . Since GAMA2, GAMA3, and NACP sulfoxide are isomeric, and do not give unique fragments on LC-MS, chromatographic resolution of these materials was required. For each of the two ACRYLAMIDE KINETICS IN HUMANS 259 isomers of the N-acetylcysteine conjugates of GA, two diastereomers could be resolved.
13 C 3 -NACP sulfoxide is also present as a pair of diastereomers, and is isomeric with the N-acetylcysteine conjugates of 13 C 3 -GA. Thus, a total of six peaks appear in common in Figure 2E and 2F. The peaks for each isomer/diastereomer could be clearly resolved chromatographically. The major GA conjugate (GAMA3), which corresponds to metabolite 2 (Sumner et al., 1992) , was present as two peaks at 11.9 and 12.3 min (Fig. 2E) . GAMA2, which corresponds to metabolite 3 (Sumner et al., 1992) , was present as two peaks at 8.3 and 8.8 min (Fig. 2F) .
13 C 3 -NACP sulfoxide was present as a pair of diastereomers at 6.8 and 7.3 min (Fig. 2F) .
The analytical approach used in this study in which unlabeled internal standard was added to each sample has the potential to have slight errors due to the potential contribution of metabolites of exogenous unlabeled dietary AM. However, given the relatively high concentration of standards added, and the low levels of AM metabolites that are likely in the normal background urine, it is unlikely that this will be a significant source of error. have recently reported median levels of NACP of 60 lg/l (range of 3-338 lg/l). The levels of NACP used as internal standard in this study were 60 lg/ml. have also recently reported median levels of GAMA3 of 8 lg/l (range of < LOD ÿ 45 lg/l). The level of GAMA3 used as internal standard in this study was 20 lg/ml. Therefore, we expect that the background of metabolites from dietary AM would not interfere significantly with the measurements made in this study.
Oral Administration
In urine samples following oral intake of AM, the following were measured: AM, GA, NACP and its S-oxide, and two isomers of the GA mercapturic acids. Unchanged 13 C 3 -AM accounted for approximately 9-10% of the urinary metabolites measured (Table 1 ). The elimination of AM in urine occurred at early time points, with the majority excreted by 4 h. 13 C 3 -GA accounted for approximately 1% of the urinary metabolites. Low levels of the AM cysteine conjugate, 13 C 3 -CP, were detected accounting for 0.4-0.6% of the urinary metabolites. As described previously for a limited number of samples (Fennell et al., 2005) , the major metabolite of AM was NACP. This metabolite accounted for 68-69% of the excreted metabolites measured in all three dose groups. The sulfoxide of NACP, which had been previously reported in human urine (Fennell et al., 2005) , accounted for 17-19% of the urinary metabolites. The two mercapturic acid conjugates of GA together accounted for less than 2% of the metabolites in urine. The predominant form of this conjugate was the 3-substituted form (GAMA3). The recovery of AM and its metabolites in urine following oral administration expressed as a percentage of the administered dose was 39.9 ± 9.9% at the high dose, to 49.9 ± 6.3% at the mid dose, and 45.6 ± 8.5% at the low dose.
Pharmacokinetic analysis of the excretion of AM was conducted, using a noncompartmental model. The rate of elimination and the elimination half-life estimated at each exposure level were similar, with the mean half-life ranging from 3.1 to 3.5 h (Table 2 ). In contrast to AM, which was eliminated primarily in the 0-2 and 2-4 h urine samples, the maximal amounts of the metabolites were eliminated in the 8-16 h samples. Analysis of the formation and elimination of metabolites was beyond the scope of a simple noncompartmental analysis. a Values represent mean ± SD (n ¼ 5 subjects).
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Dermal Administration
In the majority of samples of urine from volunteers receiving AM dermally, GA was not detected (Table 3) . AM was not detected in the 0-2 h sample from the first day of administration. The only metabolite that appeared in the 0-2 h sample was 13 C 3 -CP, which was detected at low levels in urine samples at first time point from three of the five exposed individuals. The concentration detected was above the LOD, but below LOQ, and has been included in Table 3 for completeness. In the 2-4 h sample collected on the first day, both AM and CP were detectable. NACP and its sulfoxide were not detectable until the 4-8 h urine samples from day 1. The GA mercapturic acids were not detectable until the 8-16 h samples. NACP was the largest metabolite excreted in urine, accounting for 69.7% of the urinary metabolites. NACP sulfoxide was the next most abundant metabolite, accounting for 22.4% of the urinary metabolites. Approximately 4% was recovered as AM, and approximately 3% was derived from GA (GA and its mercapturic acid metabolites, glyceramide was not measured). The rate of excretion (lmol/h, Fig. 3 ) of NACP was maximal on day 3, following the third administration of AM dermally. AM and its metabolites were excreted on day 4, indicating that up to 2 days following the last dermal dose, AM was being absorbed and excreted. However, the rate of excretion of AM dropped from a peak of 0.27 lmol/h reached on day 3 to 0.016 lmol/h at the end of day 4, suggesting that absorption and elimination of AM were nearing completion.
In our previous study, we had reported two measures of dose: the applied dose, which consisted of the AM applied to the skin; the absorbed dose, which consisted of the AM applied to the skin-the AM washed off the skin at the end of the exposure. The recovered urinary metabolites accounted for Values are total lmol measured in each urine sample (mean ± SD, n ¼ 5 subjects).
b ND was below LOQ.
c CP was detected in only three of the samples. The value represents mean ± SD, n ¼ 3 subjects.
d
GA was detected in only one of the samples, and the value represents a single value.
e GA was detected in two of the samples, the value presented is a mean of two determinations. 4.5 ± 0.8% of the applied dose (Table 4) , and 12.4 ± 3.1 of the absorbed dose (Table 5 ) (Fennell et al., 2005) .
DISCUSSION
This report provides an extension of the previous publication (Fennell et al., 2005) of urinary metabolites reported using 13 C NMR for analysis of urinary metabolites of (1,2,3-13 C 3 ) AM. The use of LC-MS/MS for the analysis has enabled quantitation of metabolites in each urine sample collected, which in turn has provided pharmacokinetic data, and a comparison of data obtained at three dose levels following oral administration, and following dermal administration. In comparing the data reported here and those reported previously, it should be noted that a single composite sample for each subject was prepared for analysis by NMR spectroscopy (reported previously), whereas individual samples collected over a number of time intervals were prepared for LC-MS/MS analysis. AM was detected but not quantitated by NMR spectroscopy, and glyceramide was not quantitated by LC-MS. Previously, we reported that 34 ± 5.7% of the dose was recovered following oral administration of AM (Fennell et al., 2005) . In this study, the recovered metabolites accounted for 39.9 ± 9.9% of the administered dose. Metabolites that were present at low concentration, and could not be quantitated by NMR, namely metabolites 2 and 3, the GA mercapturic acids, were quantitated by LC-MS.
Of considerable interest is whether the metabolism of AM changes at low doses. The oxidation of AM to GA is catalyzed by CYP2E1 (Sumner et al., 1999) , and is saturable (Calleman et al., 1993) . Studies by Calleman have suggested that the percentage of AM metabolized via GA increases dramatically with decreasing dose. While this is the case in making comparisons over the range of 0.5-100 mg/kg in rodents, in the range employed in this human study, there did not appear to be any significant differences between the doses studied with respect to the percentage of metabolites present as GA, and its mercapturic acid conjugates. Fennell et al. (2005) .
c AM was administered on day 1, day 2, and day 3, but not on day 4.
FIG. 3.
Rate of urinary excretion of 13 C 3 -AM and its metabolites after dermal administration. The excretion rate was calculated from the total amount in each urine sample divided by interval between sample collection. Each sample is plotted at the midpoint of the collection time, and each data point represents the mean and standard deviation for five individuals. The upper panel shows all the metabolites measured and AM. The excretion rate of AM is expanded in the lower panel for clarity. Fennell et al. (2005) .
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AM is excreted directly in urine. Previous studies in which NMR spectroscopy was used to quantitate the metabolites of 13 C 3 AM had detected but not quantitated AM. This was because of the long relaxation time of AM. In the current study, we have quantitated AM excreted with time, and conducted a pharmacokinetic analysis of AM. The half-life or elimination rate constant of AM has been estimated previously in a number of publications. Calleman (1996) estimated that the elimination rate constant of AM in humans was 0.23 h ÿ1 by extrapolation from data obtained in rats. Our measurements ranged from 0.21 to 0.26 h ÿ1 , or half-lives of 3.1-3.5 h. Sorgel et al. (2002) reported half-lives of AM in two subjects of 2.2 and 7 h, following ingestion of AM-containing food. Fuhr et al. (2006) recently reported a half-life of 2.4 ± 0.4 h for AM following ingestion of AM-containing food.
AM is rapidly taken up and excreted in urine, following oral administration. This contrasts with dermal exposure, in which there is a lag period of several hours before AM appears in the urine. This is consistent with the time required for AM to cross the stratum corneum and penetrate the dermis. One of the motivating factors for measuring the AM metabolites in urine was that the systemic availability derived from hemoglobin adduct measurements was approximately 6.6% of that estimated if the dermally administered dose was entirely absorbed (Fennell et al., 2005) . Since the extent of adduct formation depends on area under the curve in blood, which in turn depends on the dose taken up, and the rate of elimination, verification of the extent of uptake and elimination of urinary metabolites was necessary to substantiate the measurement of availability from hemoglobin adduct measurements. In this study, approximately 4.5% of the dermally administered dose was recovered as urinary metabolites. When a more refined dose metric of dermally absorbed dose was compared with hemoglobin adduct measurements, an estimate of 17.0% availability was obtained (Fennell et al., 2005) . Approximately 12.35% of the absorbed dose was recovered as urinary metabolites measured by LC-MS. Thus, it appears that the absorption of AM estimated from urinary metabolites and from hemoglobin adducts is consistent. The values obtained in this study indicate that the estimates that have been used in risk assessments for AM as a result of dermal exposure, e.g., 75% (European Union, 2002) , appear to be overly conservative.
A limitation of the approach taken in analyzing the urinary metabolites by LC-MS/MS was that we did not succeed in quantitating glyceramide in urine. Since glyceramide accounts for a considerable fraction of the metabolism of GA following oral administration, it is not possible to estimate the fractions of AM administered metabolized by direct GSH conjugation and that via oxidation to GA. Previously, after analysis of urinary metabolites by NMR spectroscopy we reported that glyceramide accounted for approximately 11% of the urinary metabolites following oral administration of 3 mg/kg AM, and for approximately 80% of the GA-derived metabolites detected (Fennell et al., 2005) . Development of a sensitive method for quantitation of glyceramide in urine is a priority for assessing metabolism via GA in humans.
In this study, a lag between the first application of 1,2,3-13 C 3 AM dermally and the appearance of AM and its metabolites in the urine was apparent. This lag is consistent with the time required for AM to penetrate the stratum corneum and to penetrate the dermis. The percutaneous absorption of chemicals is frequently described as a steady-state diffusion process following Fick's Law. However, the steady state condition is achieved some time after the initial contact with the skin. The lag time required to reach steady-state conditions can be estimated based on the path length of chemical diffusion, commonly the thickness of the stratum corneum, and diffusion coefficient in the membrane. A lag time of 0.24 h has been estimated based on the physicochemical properties of AM (Hoang, 1992) . Organic chemicals can form a reservoir in the stratum corneum, resulting in slow release to the systemic circulation (Hadgraft, 1979) . The time course of appearance of AM and its metabolites in urine is consistent with a slow release of AM from the skin. The application of AM was terminated at 72 h, and urine was collected for a further 24 h following the end of the exposure. While AM metabolites were still being eliminated at the end of day 4, the rate of excretion of AM dropped from a peak of 0.27 lmol/h reached on day 3 to 0.016 lmol/h at the end of day 4. The rate of formation of hemoglobin adducts during the same period resulted in a decline, estimated from the mean difference in AAVal and GAVal between each day and the preceding day (Fig. 4) . The rate of formation was maximal on days 3 and 4, following the second and third dermal applications of AM. On day 5, after removal of the last application of AM, the increment formed has fallen considerably compared with the days during which an application took place.
Interestingly, S-(3-amino-3-oxopropyl)cysteine was detected earliest in urine following dermal exposure, in the absence of AM, suggesting that glutathione conjugation may occur in skin. Complete first pass metabolism in the skin at low levels of dermal exposure is a possibility. Skin contains GSH, is known to express GSH transferases, and has the capability to metabolize substrates such as dinitrochlorobenzene in vitro (Jewell et al., 2000) . AM applied dermally is known to decrease the concentration of GSH in skin (Mukhtar et al., 1981) .
It is clear from this study that the extent of metabolism of AM via GA in humans is considerably lower than that reported following oral administration in rats (41% at 3 mg/kg) and mice (59% at 50 mg/kg) (Fennell et al., 2005; Sumner et al., 1992) . A number of recent reports have appeared which describe the measurement of the mercapturic acid metabolites of AM and GA in the urine of smokers and nonsmokers, in the urine of an individual who had ingested 1 mg deuterated AM, and in the urine of volunteers who ingested food containing 1 mg AM (summarized in Table 6 ). In the study reported by Bjellaas et al. (2005) , GAMA3 and NACP were detected and quantitated in urine from one smoker and five nonsmokers. Urine samples were collected at intervals over 3 days, during which the volunteers fasted between breakfast on day 1 and breakfast on day 2. The ratio of GAMA3:NACP was reported as 0.46 for nonsmokers in this study. It is possible that the period of fasting may alter CYP2E1 activity, although conflicting effects of fasting on CYP2E1 activity have been reported in rats (O'Shea et al., 1994) and in humans (Wan et al., 2006) . Boettcher et al. NACP and GAMA are reported as mean lmol. f GAMA includes both GAMA2 and GAMA3.
FIG. 5. LC-MS/MS detection of natural-abundance NACP sulfoxide, GAMA3, and GAMA2 in the negative ion mode. Chromatography was conducted as described in Methods, and detection was conducted using a precursor / product ion transition of m/z 249 / 120. ACRYLAMIDE KINETICS IN HUMANS (2005) reported that the median concentration of the mercapturic acids of AM (NACP) and GA (GAMA, assigned as Nacetyl-S-(2-hydroxy-2-carbamoylethyl)cysteine) was 60 and 8 lg/l, respectively, in urine. The ratio of GAMA:NACP for individual samples was reported to be between 0 and 0.5 , with a median ratio of 0.16. Following ingestion of 1 mg d 3 -AM by a single volunteer, urine samples were collected for 2 days, and the excretion of d 3 -NACP and d 3 -GAMA in urine was measured by LC-MS/MS . A total of 56.2% of the dose administered was recovered as urinary metabolites, with 4.6% as d 3 -GAMA, and 51.7% as d 3 -NACP. In the first 22 h following administration, 2.7% of the administered dose was excreted as d 3 -GAMA. This corresponds to the observation of 0.5-0.7% of the dose following oral administration, eliminated as GAMA3 in this study. It appears that the extent of metabolism as a result of conversion to GA and its mercapturic acids in this study was lower than that reported by others. Following administration of AM (1 mg) in food to volunteers, AM, NACP, and GAMA3 excreted in urine accounted for 4, 50, and 6% of the dose (Fuhr et al., 2006) (GAMA:NACP of 0.118). Urban et al. (2006) described a GAMA:NACP ratio of 0.23 for nonsmokers and 0.15 for nonsmokers. In contrast with the previous studies, we report a ratio of GAMA:NACP of 0.024-0.026. While the differences could result from differences between administered AM, versus the low doses of AM in food, or from the sampling time following ingestion of AM, the method used for analysis may be a significant factor. The method reported here includes analysis of NACP sulfoxide in addition to GAMA2 and GAMA3. These metabolites give the same molecular ion, and have many fragments in common. Chromatographic separation is thus required for quantitation. For the natural-abundance forms of these three metabolites with analysis by LC-MS/MS in the negative ion mode, we have observed (Fig. 5 ) that peaks for NACP sulfoxide, GAMA2, and GAMA3 are visible when monitoring m/z 249 / 120 (conditions similar to those used by to quantitate GAMA3). measured NACP and GAMA3 in urine in smokers and nonsmokers using negative ion LC-MS/MS monitoring m/z 249 / 120, with an LC system resolved a single peak for GAMA3 at 9.25 min and NACP at 11.86 min. It is possible that NACP sulfoxide is not resolved chromatographically from GAMA3 under those conditions, and thus could be quantitated inadvertently as GAMA3. This same method has been used in a number of publications Fuhr et al., 2006) .
While NACP and GAMA have been used as urinary metabolites for monitoring exposure to AM, and to characterize metabolism to GA, it is apparent from this study that NACP sulfoxide should be included in the measurement of metabolites in urine. Since hydrolysis appears to account for the majority of the GA metabolites in urine (Fennell et al., 2005) , development of a method for analysis of glyceramide in urine should be a priority.
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